[Combination antimetabolite-alkylating agent-vinblastine in the treatment of advanced breast cancer].
The results obtained in 14 patients suffering from hormone-resistant metastatic breast cancer treated with the following association: methotrexate (5-fluorouracyl in case of methotrexate intolerance), cyclophosphamide, vinblastin administered i.v. once every 10-13 days, are reported. 4 objective regression (29%) were observed but survival did not very appreciably differing therapy. In 9 cases (65%) intolerance of various types was observed but in 8 these signs regressed in a short time and the therapy was resumed.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use*; D000963:Antimetabolites / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use*
D000477:Alkylating Agents; D000963:Antimetabolites; D014747:Vinblastine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
L'associazione antimetabolita-alchilante-veleno del fuso nel trattamento del cancro mammario in fase avanzata